Revvity has logged strong share gains in recent years, which naturally puts the spotlight on whether the current price lines up with the cash the business is expected to generate. With the stock near recent highs, the question is how that performance squares with an intrinsic value view built from its cash flows.
-
Over the past 3 years the stock has returned 99.0%, which puts a lot of expectations about Revvity's future cash generation under the microscope.
-
The launch of the Signals LabGistics workflow orchestration tool brings AI deeper into Revvity's offering, which can influence how investors think about the timing, durability and scalability of its future cash flows.
-
What if you looked at Revvity through its earnings instead? See what Revvity's 77.9x P/E says about the price .
For investors, the debate is whether Revvity's current share price is fully supported by the intrinsic value suggested by its projected cash flows.
If you are weighing Revvity's cash flow story against similar AI themed workflows, compare it with other 36 healthcare AI stocks .
Has Revvity Run Too Far on Cash Flow?
The Discounted Cash Flow (DCF) approach here focuses on the cash Revvity can return to shareholders over time. Latest twelve month free cash flow sits at about $545.6 million, with the model assuming that this pool of cash grows rather than shrinks over the coming decade. On those projections, the DCF output suggests an intrinsic value that is meaningfully below today's trading level of $165.78.
The cash flow curve is not explosive in the model. Instead, it points to a steady build from current levels, which can matter if you are expecting faster payback from an AI heavy workflow story. The launch of Signals LabGistics brings a clear AI angle into Revvity's lab software footprint. However, the DCF still treats future free cash flow as growing at a measured pace, which helps explain why the estimated intrinsic worth trails the share price. Find out what Revvity could be worth using our Discounted Cash Flow (DCF) estimate .
The Revvity Narrative: What Would Justify Today's Price?
Narratives on Revvity pick up where the DCF puzzle leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or less than it is today on Simply Wall St's Community page. Instead of a single output from one ratio or model, they lay out the future that number relies on so you can watch how closely reality tracks that picture over time.
Revvity's community splits between investors who see AI heavy tools and diagnostics leaving more upside on the table and others who think that strength is already reflected in the price.
Bull case: 5% undervalued
"Revvity's growing backlog in high content screening instruments, including the new Opera Phenix OptIQ flagship system, signals that customers are starting to retool labs for higher throughput AI era data generation…"
Discover why this Narrative puts Revvity at 5% undervalued .
Bear case: 12% overvalued
"The current valuation suggests that investors are already paying a premium for sustained growth in areas such as Signals software, reproductive health, and ex-China immunodiagnostics, even though the company's longer-term revenue and EPS trends have been under pressure…"
Explore why this Narrative puts Revvity at 12% overvalued .
One more key question on Revvity that the valuation does not answer
Revvity's cash flow picture is only part of the story, as internal checks have also flagged areas of concern that could matter for investors who care about risk as much as price. Take a closer look at 2 warning signs before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RVTY .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
